SCHEMBL6842484

SCHEMBL6842484

O=C1NC(=O)C(C(O)c2ccc(-c3cnc4ccccc4c3)cc2)N1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 1/20 0.45
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
PDGFRB P09619 2/20 0.43
PDGFRA P16234 2/20 0.43
NR2F2 P24468 1/20 0.42
PIK3CD O00329 1/20 0.40
PIK3CA P42336 1/20 0.40
MAP4K4 O95819 1/20 0.39
CSNK1G2 P78368 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
MAP4K5 Q9Y4K4 1/20 0.39
TOP2A P11388 1/20 0.39
TOP2B Q02880 1/20 0.39
FASN P49327 2/20 0.39
AKR1C3 P42330 1/20 0.39
AKR1C2 P52895 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6798968 0.80 HSD17B2 (0.40)
SCHEMBL6791191 0.75 MMP2 (0.35) TDP2BRD4
SCHEMBL10620249 0.74 ALDH1A1 (0.41) CA2
SCHEMBL2869477 0.72 ALDH1A1 (0.45) TDP2NR2F2MAP4K4CSNK1G2CLK4
SCHEMBL6797785 0.70 TDP2 (0.43) TDP2CA12CA1CA2CA9
SCHEMBL6841040 0.69 MEN1 (0.35)
SCHEMBL24621829 0.68 PDGFRB (0.72) TDP2CA12CA1CA2CA9
SCHEMBL29375510 0.68 PDGFRB (0.72) TDP2CA12CA1CA2CA9
SCHEMBL26829682 0.68 PDGFRB (0.72) TDP2CA12CA1CA2CA9
SCHEMBL32667946 0.67 PDGFRB (0.77) TDP2CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
EP-1370536-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
EP-1370538-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074752-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed
WO-2002074750-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 TDP2 3806/4885CA12 415/4885CA1 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.